US biotechnology trade group BIO calls for renewal of one-time $1 billion tax credit
The USA’s Biotechnology Industry Organization (BIO) last week made a call for Congress to repeat a one-time $1 billion program that provides tax credits to small companies that are developing new drugs, saying this will have a positive impact on advancing life-saving therapies and cures for patients, and US biotechnology competitiveness, while helping sustain and create jobs.
Under the Therapeutic Discovery Project passed in March as part of the US health-care overhaul, $5 million in grants or tax credits will be awarded to drug companies with 250 or fewer employees to support work developing new therapies. Recipients in the current program are to be notified by the Internal Revenue Service.
The chief executives of eligible biotech companies also say the program increases the likelihood that they will keep their operations in the USA. The new findings of a survey were released by the BIO, which said that recipients of the awards are expected to be announced by early next week.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze